Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Xaliproden

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Xaliproden?

Xaliproden is an investigational drug.

There have been 5 clinical trials for Xaliproden. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2002.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Dementia, and Alzheimer Disease. The leading clinical trial sponsors are Sanofi and [disabled in preview].

Recent Clinical Trials for Xaliproden
Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based RegimensSanofiPhase 3
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.SanofiPhase 3
18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeSanofiPhase 3

See all Xaliproden clinical trials

Clinical Trial Summary for Xaliproden

Top disease conditions for Xaliproden
Top clinical trial sponsors for Xaliproden

See all Xaliproden clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.